Macason Etok

Macason Etok asked about the margin profile and adoption potential of the Qkine partnership products, especially with CellSeal vials, and if CryoCase could reduce scrap and improve margins long-term by replacing bags on the front end.

Answer

Chairman and CEO Roderick de Greef declined to speak specifically about Qkine margins but noted a profile reflecting anticipated volume. He stated that the combination of Qkine cytokines with CellSeal vials is a 6-9 month development project, with revenue impact expected late 2026 or early 2027, emphasizing it's a long-term strategic move. He clarified that CryoCase is for final product to patient, while the Rigid Container (RCC) is being designed to replace bags for shipping product from BioLife to customers, which is 18-24 months away, and current bag yield remediation is process-oriented.